| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
87,080,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Co.'s compound, batoclimab, is a human, monoclonal antibody targeting the neonatal fragment crystallizable receptor. Co.'s product candidate, batoclimab, has been dosed in small volumes (e.g., two mL) and with a 27-gauge needle, while still generating therapeutically relevant pharmacodynamic activity. Co. is developing batoclimab for Myasthenia Gravis, Thyroid Eye Disease and Warm Autoimmune Hemolytic Anemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,526,316 |
1,977,983 |
| Total Buy Value |
$0 |
$0 |
$58,000,008 |
$60,700,210 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
4 |
| Total Shares Sold |
121,451 |
211,093 |
494,767 |
657,606 |
| Total Sell Value |
$3,709,409 |
$7,040,317 |
$13,330,723 |
$15,815,635 |
| Total People Sold |
7 |
10 |
10 |
10 |
| Total Sell Transactions |
16 |
30 |
46 |
72 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Levine Mark S. |
Chief Legal Officer |
• – – |
2024-01-26 |
4 |
S |
$37.91 |
$114,778 |
D/D |
(3,027) |
304,102 |
|
- |
|
| Geffner Michael |
Chief Medical Officer |
• – – |
2024-01-26 |
4 |
S |
$37.91 |
$383,012 |
D/D |
(10,101) |
89,899 |
|
- |
|
| Macias William L. |
Chief Medical Officer |
• – – |
2024-01-18 |
4 |
S |
$41.03 |
$17,397 |
D/D |
(424) |
333,173 |
|
- |
|
| Barnett Eva Renee |
Chief Financial Officer |
• – – |
2024-01-11 |
4 |
S |
$41.64 |
$147,023 |
D/D |
(3,515) |
323,350 |
|
- |
|
| Salzmann Peter |
Chief Executive Officer |
• • – |
2024-01-05 |
4 |
S |
$38.59 |
$147,568 |
D/D |
(3,824) |
944,685 |
|
- |
|
| Butchko Julia G. |
Chief Development Officer |
• – – |
2024-01-05 |
4 |
S |
$38.59 |
$50,051 |
D/D |
(1,297) |
409,963 |
|
- |
|
| Migausky George V |
Director |
– • – |
2023-12-01 |
4 |
AS |
$38.79 |
$504,567 |
D/D |
(12,700) |
109,808 |
|
- |
|
| Pande Atul |
Director |
– • – |
2023-12-01 |
4 |
AS |
$38.80 |
$490,668 |
D/D |
(12,350) |
83,158 |
|
- |
|
| Fromkin Drew J |
Director |
– • – |
2023-12-01 |
4 |
AS |
$38.78 |
$490,697 |
D/D |
(12,350) |
88,658 |
|
- |
|
| Macias William L. |
Chief Medical Officer |
• – – |
2023-11-22 |
4 |
S |
$32.75 |
$107,024 |
D/D |
(3,265) |
333,597 |
|
- |
|
| Barnett Eva Renee |
Chief Financial Officer |
• – – |
2023-11-22 |
4 |
S |
$32.75 |
$132,920 |
D/D |
(4,055) |
326,865 |
|
- |
|
| Salzmann Peter |
Chief Executive Officer |
• • – |
2023-11-22 |
4 |
S |
$32.75 |
$531,581 |
D/D |
(16,217) |
948,509 |
|
- |
|
| Butchko Julia G. |
Chief Development Officer |
• – – |
2023-11-22 |
4 |
S |
$32.75 |
$107,024 |
D/D |
(3,265) |
411,260 |
|
- |
|
| Levine Mark S. |
Chief Legal Officer |
• – – |
2023-11-22 |
4 |
S |
$32.75 |
$106,598 |
D/D |
(3,252) |
307,129 |
|
- |
|
| Levine Mark S. |
Chief Legal Officer |
• – – |
2023-10-25 |
4 |
S |
$34.66 |
$142,349 |
D/D |
(4,107) |
310,381 |
|
- |
|
| Macias William L. |
Chief Medical Officer |
• – – |
2023-10-19 |
4 |
S |
$36.80 |
$19,504 |
D/D |
(530) |
336,862 |
|
- |
|
| Barnett Eva Renee |
Chief Financial Officer |
• – – |
2023-10-10 |
4 |
S |
$36.92 |
$168,244 |
D/D |
(4,557) |
330,920 |
|
- |
|
| Butchko Julia G. |
Chief Development Officer |
• – – |
2023-10-05 |
4 |
S |
$35.54 |
$62,885 |
D/D |
(1,735) |
414,525 |
|
- |
|
| Salzmann Peter |
Chief Executive Officer |
• • – |
2023-10-05 |
4 |
S |
$35.54 |
$189,887 |
D/D |
(5,239) |
964,726 |
|
- |
|
| Roivant Sciences Ltd. |
|
• • • |
2023-10-02 |
4 |
B |
$38.00 |
$58,000,008 |
D/D |
1,526,316 |
79,805,331 |
0.01 |
- |
|
| Roivant Sciences Ltd. |
|
• • • |
2023-10-02 |
4 |
A |
$38.00 |
$169,999,992 |
D/D |
4,473,684 |
78,279,015 |
|
- |
|
| Levine Mark S. |
Chief Legal Officer |
• – – |
2023-08-24 |
4 |
S |
$20.30 |
$249,406 |
D/D |
(12,286) |
314,488 |
|
- |
|
| Macias William L. |
Chief Medical Officer |
• – – |
2023-08-24 |
4 |
S |
$20.30 |
$250,360 |
D/D |
(12,333) |
337,392 |
|
- |
|
| Butchko Julia G. |
Chief Development Officer |
• – – |
2023-08-24 |
4 |
S |
$20.30 |
$250,360 |
D/D |
(12,333) |
416,260 |
|
- |
|
| Barnett Eva Renee |
Chief Financial Officer |
• – – |
2023-08-24 |
4 |
S |
$20.30 |
$292,036 |
D/D |
(14,386) |
335,477 |
|
- |
|
182 Records found
|
|
Page 2 of 8 |
|
|
